← Leaderboards
Roberta Diaz Brinton
University Of Arizona
$56,323,258
Attributed
$97,820,003
Total exposure
36
Grants
30
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $17.1M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$141,335,887 · 37
By mechanism
P01$59,956,890 · 15
R01$52,410,946 · 5
RF1$5,887,658 · 1
U01$5,240,643 · 2
R37$3,682,361 · 1
R44$2,536,705 · 1
Top collaborators
- Kathleen E. Rodgers12 shared
- Lisa Mosconi9 shared
- Lon S Schneider6 shared
- Rui Chang5 shared
- Gerson David Hernandez4 shared
- Frederick T Boyd3 shared
- John Rinehart3 shared
- Demetra Skaltsas2 shared
Most similar at University Of Arizona
Same institution · by research overlap
- Patricia B Hoyer$6,157,492
- Gerson David Hernandez$2,098,361
- Lisa Mosconi$10,441,680
- Scott B Going$7,642,039
- Schantel Williams$433,803
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseBrainProgramsPreventAgingWomanMetabolicDesignAging BrainMissionFemaleBioenergeticsPerimenopauseTranslatingPathway InteractionsPhenotypeLeadPathologyS Disease RiskBaseBiologicalPre-ClinicalTranslational Research
Grant awards (171)
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial$6,580,973
R01 · FY2025 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$2,919,843
P01 · FY2025 · AG · contact PI
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial$1,301,410
R01 · FY2025 · AG · contact PI
Regulatory and Human Study Operations (RHSO) Core C$1,044,420
U19 · FY2025 · AG · contact PI
Aging and Estrogenic Control of the Bioenergetic System in Brain$526,505
R37 · FY2025 · AG · contact PI
Project 2: Metabolic and Immune Systems of Biology Interactions as Initiators and Drivers of Alzheimer's Pathology in Brain: Therapeutic Targets and Windows$511,639
P01 · FY2025 · AG · contact PI
Research Education Component$344,707
P30 · FY2025 · AG · contact PI
Translational Research in Alzheimer's Disease and related Dementias (TRADD)$297,408
T32 · FY2025 · AG · contact PI
Diversity in Research Education in Aging Medicine and Science$288,268
R25 · FY2025 · AG
Administrative$63,731
P01 · FY2025 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$3,045,124
P01 · FY2024 · AG · contact PI
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial$1,327,969
R01 · FY2024 · AG · contact PI
Project 2: Metabolic and Immune Systems of Biology Interactions as Initiators and Drivers of Alzheimer's Pathology in Brain: Therapeutic Targets and Windows$580,832
P01 · FY2024 · AG · contact PI
Aging and Estrogenic Control of the Bioenergetic System in Brain$537,250
R37 · FY2024 · AG · contact PI
Translational Research in Alzheimer's Disease and related Dementias (TRADD)$305,754
T32 · FY2024 · AG · contact PI
Diversity in Research Education in Aging Medicine and Science$288,268
R25 · FY2024 · AG
Regulatory and Human Study Operations (RHSO) Core C$287,146
U19 · FY2024 · AG · contact PI
Research Education Component$183,801
P30 · FY2024 · AG · contact PI
Administrative$73,074
P01 · FY2024 · AG · contact PI
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial$7,279,977
R01 · FY2023 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$3,085,066
P01 · FY2023 · AG · contact PI
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial$1,544,481
R01 · FY2023 · AG · contact PI
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health$1,199,342
R44 · FY2023 · AG
Project 2: Metabolic and Immune Systems of Biology Interactions as Initiators and Drivers of Alzheimer's Pathology in Brain: Therapeutic Targets and Windows$572,124
P01 · FY2023 · AG · contact PI
Aging and Estrogenic Control of the Bioenergetic System in Brain$537,250
R37 · FY2023 · AG · contact PI
Novel Intranasal Formulations of Allopregnanolone, a Regenerative Therapeutic for Alzheimer's Disease$505,836
R43 · FY2023 · AG
Translational Research in Alzheimer's Disease and related Dementias (TRADD)$294,459
T32 · FY2023 · AG · contact PI
Regulatory and Human Study Operations (RHSO) Core C$279,471
U19 · FY2023 · AG · contact PI
Undergraduate Readying for Burgeoning Research for American Indian Neuroscientists$236,515
R25 · FY2023 · NS
Administrative$73,074
P01 · FY2023 · AG · contact PI
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial$7,552,351
R01 · FY2022 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$3,016,302
P01 · FY2022 · AG · contact PI
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial$2,121,223
R01 · FY2022 · AG · contact PI
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health$1,337,363
R44 · FY2022 · AG
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal Endophenotype$1,130,295
R01 · FY2022 · AG · contact PI
Project 2: Metabolic and Immune Systems of Biology Interactions as Initiators and Drivers of Alzheimer's Pathology in Brain: Therapeutic Targets and Windows$571,131
P01 · FY2022 · AG · contact PI
Aging and Estrogenic Control of the Bioenergetic System in Brain$537,250
R37 · FY2022 · AG · contact PI
Regulatory and Human Study Operations (RHSO) Core C$279,471
U19 · FY2022 · AG · contact PI
Undergraduate Readying for Burgeoning Research for American Indian Neuroscientists$236,515
R25 · FY2022 · NS
Translational Research in AD and related Dementias (TRADD)$208,692
T32 · FY2022 · AG · contact PI
Administrative$152,814
P01 · FY2022 · AG · contact PI
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial$7,370,815
R01 · FY2021 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$3,042,893
P01 · FY2021 · AG · contact PI
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal Endophenotype$1,107,464
R01 · FY2021 · AG · contact PI
Project 2: Metabolic and Immune Systems of Biology Interactions as Initiators and Drivers of Alzheimer's Pathology in Brain: Therapeutic Targets and Windows$570,176
P01 · FY2021 · AG · contact PI
Aging and Estrogenic Control of the Bioenergetic System in Brain$307,887
R37 · FY2021 · AG · contact PI
Translational Research in AD and related Dementias (TRADD)$303,593
T32 · FY2021 · AG · contact PI
Regulatory and Human Study Operations (RHSO) Core C$287,146
U19 · FY2021 · AG · contact PI
Undergraduate Readying for Burgeoning Research for American Indian Neuroscientists$238,809
R25 · FY2021 · NS
Research Education Component$190,681
P30 · FY2021 · AG · contact PI
Administrative$157,456
P01 · FY2021 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$2,496,919
P01 · FY2020 · AG · contact PI
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal Endophenotype$1,134,417
R01 · FY2020 · AG · contact PI
Perimenopause in APOE4 Brain: Clinical Outcomes and Global Impact (Project 3)$440,489
P01 · FY2020 · AG · contact PI
Aging and Estrogenic Control of the Bioenergetic System in Brain$308,390
R37 · FY2020 · AG · contact PI
Translational Research in AD and related Dementias (TRADD)$300,250
T32 · FY2020 · AG · contact PI
Perimenopause in ApoE4 Brain: Bioenergetic Crisis and Inflammation$299,673
P01 · FY2020 · AG · contact PI
Administrative Core A$276,750
P01 · FY2020 · AG · contact PI
Undergraduate Readying for Burgeoning Research for American Indian Neuroscientists$246,522
R25 · FY2020 · NS
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial$8,410,912
R01 · FY2019 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$2,064,572
P01 · FY2019 · AG · contact PI
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal Endophenotype$1,141,341
R01 · FY2019 · AG · contact PI
Novel formulations of Allopregnanolone to treat Alzheimer's Disease$449,886
R43 · FY2019 · AG
Perimenopause in APOE4 Brain: Clinical Outcomes and Global Impact (Project 3)$314,129
P01 · FY2019 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$314,129
P01 · FY2019 · AG · contact PI
Aging and Estrogenic Control of the Bioenergetic System in Brain$308,856
R37 · FY2019 · AG · contact PI
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal Endophenotype$300,580
R01 · FY2019 · AG · contact PI
Translational research in Alzheimerâs Disease and Related Dementias (TRADD)$296,984
T32 · FY2019 · AG · contact PI
Perimenopause in ApoE4 Brain: Bioenergetic Crisis and Inflammation$295,443
P01 · FY2019 · AG · contact PI
Administrative Core A$277,028
P01 · FY2019 · AG · contact PI
Undergraduate Readying for Burgeoning Research for American Indian Neuroscientists$254,799
R25 · FY2019 · NS
Metabolic Networks and Pathways Predictive of Sex Differences in AD Risk and Responsiveness to Treatment$5,887,658
RF1 · FY2018 · AG
Perimenopause in Brain Aging and Alzheimer's Disease$2,070,810
P01 · FY2018 · AG · contact PI
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal Endophenotype$1,192,861
R01 · FY2018 · AG · contact PI
Aging and Estrogenic Control of the Bioenergetic System in Brain$309,287
R37 · FY2018 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$298,665
P01 · FY2018 · AG · contact PI
Perimenopause in ApoE4 Brain: Bioenergetic Crisis and Inflammation$291,335
P01 · FY2018 · AG · contact PI
Administrative Core A$277,295
P01 · FY2018 · AG · contact PI
Allopregnanolone a Regenerative Therapy for Alzheimer's: FDA-Required Toxicology$239,276
U01 · FY2018 · AG · contact PI
Translational Research in AD and related Dementias (TRADD)$146,898
T32 · FY2018 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$2,063,197
P01 · FY2017 · AG · contact PI
Allopregnanolone a Regenerative Therapy for Alzheimer's: FDA-Required Toxicolog$354,032
U01 · FY2017 · AG · contact PI
Aging and Estrogenic Control of the Bioenergetic System in Brain$309,686
R37 · FY2017 · AG · contact PI
Perimenopause in ApoE4 Brain: Bioenergetic Crisis and Inflammation$287,209
P01 · FY2017 · AG · contact PI
Administrative Core A$277,556
P01 · FY2017 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$2,094,712
P01 · FY2016 · AG · contact PI
Allopregnanolone a Regenerative Therapy for Alzheimer's: FDA-Required Toxicolog$765,963
U01 · FY2016 · AG · contact PI
Administrative Core A$289,682
P01 · FY2016 · AG · contact PI
Perimenopause in ApoE4 Brain: Bioenergetic Crisis and Inflammation$283,474
P01 · FY2016 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$1,970,713
P01 · FY2015 · AG · contact PI
Allopregnanolone a Regenerative Therapy for Alzheimer's: FDA-Required Toxicolog$776,163
U01 · FY2015 · AG · contact PI
ANIMAL CORE$367,078
P01 · FY2015 · AG · contact PI
ANALYTIC CORE$357,891
P01 · FY2015 · AG · contact PI
PERIMENOPAUSE AND BIOENERGETIC AGING PHENOTYPES IN BRAIN AND ALZHEIMER'S RISK$335,369
P01 · FY2015 · AG · contact PI
PERIMENOPAUSE, OVARIAN HORMONES, AND OBESITY: INTERACTIVE REGULATORS OF ALZHEIMER$263,750
P01 · FY2015 · AG · contact PI
PERIMENOPAUSE AND GLIAL INFLAMMATORY RESPONSES THAT INTERACT WITH NEURON AGING$256,057
P01 · FY2015 · AG · contact PI
ADMINISTRATIVE CORE$203,009
P01 · FY2015 · AG · contact PI
PERIMENOPAUSAL SYMPTOMS AND BIOMARKERS AND COGNITIVE FUNCTION IN POSTMENOPAUSAL$187,559
P01 · FY2015 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$1,731,986
P01 · FY2014 · AG · contact PI
Allopregnanolone a Regenerative Therapy for Alzheimer's: FDA-Required Toxicolog$721,277
U01 · FY2014 · AG · contact PI
ANIMAL CORE$332,664
P01 · FY2014 · AG · contact PI
Systems Pharmacology for Predictive Alzheimer's Therapeutics: SysPharmRx-AD$329,167
R34 · FY2014 · AG · contact PI
ANALYTIC CORE$323,499
P01 · FY2014 · AG · contact PI
PERIMENOPAUSE AND BIOENERGETIC AGING PHENOTYPES IN BRAIN AND ALZHEIMER'S RISK$301,035
P01 · FY2014 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$258,624
P01 · FY2014 · AG · contact PI
PERIMENOPAUSE, OVARIAN HORMONES, AND OBESITY: INTERACTIVE REGULATORS OF ALZHEIMER$229,598
P01 · FY2014 · AG · contact PI
PERIMENOPAUSE AND GLIAL INFLAMMATORY RESPONSES THAT INTERACT WITH NEURON AGING$221,923
P01 · FY2014 · AG · contact PI
NOVEL NEUROSERMS AND NEUROARMS FOR PROTECTION AGAINST AZLHEIMER PATHOLOGY$212,291
P50 · FY2014 · AG · contact PI
ADMINISTRATIVE CORE$169,008
P01 · FY2014 · AG · contact PI
PERIMENOPAUSAL SYMPTOMS AND BIOMARKERS AND COGNITIVE FUNCTION IN POSTMENOPAUSAL$154,259
P01 · FY2014 · AG · contact PI
Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase I$2,429,633
UF1 · FY2013 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$1,632,390
P01 · FY2013 · AG · contact PI
ANIMAL CORE$313,417
P01 · FY2013 · AG · contact PI
ANALYTIC CORE$304,779
P01 · FY2013 · AG · contact PI
Estrogen-Induced Neuroprotective Mitochondrial Mechanism$298,642
R01 · FY2013 · AG · contact PI
PERIMENOPAUSE AND BIOENERGETIC AGING PHENOTYPES IN BRAIN AND ALZHEIMER'S RISK$283,612
P01 · FY2013 · AG · contact PI
PERIMENOPAUSE, OVARIAN HORMONES, AND OBESITY: INTERACTIVE REGULATORS OF ALZHEIMER$216,309
P01 · FY2013 · AG · contact PI
PERIMENOPAUSE AND GLIAL INFLAMMATORY RESPONSES THAT INTERACT WITH NEURON AGING$209,077
P01 · FY2013 · AG · contact PI
NOVEL NEUROSERMS AND NEUROARMS FOR PROTECTION AGAINST AZLHEIMER PATHOLOGY$204,420
P50 · FY2013 · AG · contact PI
ADMINISTRATIVE CORE$159,228
P01 · FY2013 · AG · contact PI
PERIMENOPAUSAL SYMPTOMS AND BIOMARKERS AND COGNITIVE FUNCTION IN POSTMENOPAUSAL$145,968
P01 · FY2013 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$54,464
P01 · FY2013 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$1,727,202
P01 · FY2012 · AG · contact PI
ANIMAL CORE$331,486
P01 · FY2012 · AG · contact PI
ANALYTIC CORE$322,354
P01 · FY2012 · AG · contact PI
Estrogen-Induced Neuroprotective Mitochondrial Mechanism$316,023
R01 · FY2012 · AG · contact PI
PERIMENOPAUSE AND BIOENERGETIC AGING PHENOTYPES IN BRAIN AND ALZHEIMER'S RISK$299,967
P01 · FY2012 · AG · contact PI
PERIMENOPAUSE, OVARIAN HORMONES, AND OBESITY: INTERACTIVE REGULATORS OF ALZHEIMER$228,785
P01 · FY2012 · AG · contact PI
PERIMENOPAUSE AND GLIAL INFLAMMATORY RESPONSES THAT INTERACT WITH NEURON AGING$221,133
P01 · FY2012 · AG · contact PI
NOVEL NEUROSERMS AND NEUROARMS FOR PROTECTION AGAINST AZLHEIMER PATHOLOGY$214,387
P50 · FY2012 · AG · contact PI
Development of Allopregnanolone as a Neurogenic Regenerative Therapeutic$173,913
U01 · FY2012 · AG · contact PI
ADMINISTRATIVE CORE$168,406
P01 · FY2012 · AG · contact PI
PERIMENOPAUSAL SYMPTOMS AND BIOMARKERS AND COGNITIVE FUNCTION IN POSTMENOPAUSAL$155,071
P01 · FY2012 · AG · contact PI
Perimenopause in Brain Aging and Alzheimer's Disease$1,719,120
P01 · FY2011 · AG · contact PI
Estrogen-Induced Neuroprotective Mitochondrial Mechanism$316,023
R01 · FY2011 · AG · contact PI
PERIMENOPAUSE AND BIOENERGETIC AGING PHENOTYPES IN BRAIN AND ALZHEIMER'S RISK$298,440
P01 · FY2011 · AG · contact PI
NOVEL NEUROSERMS AND NEUROARMS FOR PROTECTION AGAINST AZLHEIMER PATHOLOGY$215,449
P50 · FY2011 · AG · contact PI
ADMINISTRATIVE CORE$167,552
P01 · FY2011 · AG · contact PI
Development of Allopregnanolone as a Neurogenic Regenerative Therapeutic$126,383
U01 · FY2011 · AG · contact PI
Development of Allopregnanolone as a Neurogenic Regenerative Therapeutic$81,458
U01 · FY2011 · AG · contact PI
Progesterone in Brain Aging and Alzheimer's Disease$1,629,193
P01 · FY2010 · AG · contact PI
Development of Allopregnanolone as a Neurogenic Regenerative Therapeutic$465,059
U01 · FY2010 · AG · contact PI
Estrogen-Induced Neuroprotective Mitochondrial Mechanism$328,779
R01 · FY2010 · AG · contact PI
NOVEL NEUROSERMS AND NEUROARMS FOR PROTECTION AGAINST AZLHEIMER PATHOLOGY$219,038
P50 · FY2010 · AG · contact PI
PROGESTERONE AND NEUROGENIC PLASTICITY IN AGING AND AD$203,510
P01 · FY2010 · AG · contact PI
ADMINISTRATIVE CORE$141,969
P01 · FY2010 · AG · contact PI
Progesterone in Brain Aging and Alzheimer's Disease$1,602,136
P01 · FY2009 · AG · contact PI
Development of Allopregnanolone as a Neurogenic Regenerative Therapeutic$582,360
U01 · FY2009 · AG · contact PI
Estrogen-Induced Neuroprotective Mitochondrial Mechanism$333,979
R01 · FY2009 · AG · contact PI
Development of Allopregnanolone as a Neurogenic Regenerative Therapeutic$310,220
U01 · FY2009 · AG · contact PI
PROGESTERONE AND NEUROGENIC PLASTICITY IN AGING AND AD$199,715
P01 · FY2009 · AG · contact PI
ADMINISTRATIVE CORE$139,322
P01 · FY2009 · AG · contact PI
Progesterone in Brain Aging and Alzheimer's Disease$1,562,564
P01 · FY2008 · AG · contact PI
Development of Allopregnanolone as a Neurogenic Regenerative Therapeutic$644,539
U01 · FY2008 · AG · contact PI
PROGESTERONE AND NEUROGENIC PLASTICITY IN AGING AND AD$194,364
P01 · FY2008 · AG · contact PI
ADMINISTRATIVE CORE$135,589
P01 · FY2008 · AG · contact PI
Progesterone in Brain Aging and Alzheimer's Disease$1,545,703
P01 · FY2007 · AG · contact PI
Estrogen-Induced Neuroprotective Mitochondrial Mechanism$254,231
R01 · FY2007 · MH · contact PI
PROGESTERONE AND NEUROGENIC PLASTICITY IN AGING AND AD$192,553
P01 · FY2007 · AG · contact PI
ADMINISTRATIVE CORE$134,326
P01 · FY2007 · AG · contact PI
Progesterone in Brain Aging and Alzheimer's Disease$1,569,557
P01 · FY2006 · AG · contact PI
Estrogen-Induced Neuroprotective Mitochondrial Mechanism$261,825
R01 · FY2006 · MH · contact PI
ESTROGENIC STEROIDS: NEUROTROPHIC ACTION AND MECHANISM$139,794
P01 · FY2006 · AG · contact PI
PROGESTERONE AND NEUROGENIC PLASTICITY IN AGING AND AD$118,115
P01 · FY2006 · AG · contact PI
ADMINISTRATIVE CORE$82,397
P01 · FY2006 · AG · contact PI
Estrogen-Induced Neuroprotective Mitochondrial Mechanism$268,125
R01 · FY2005 · MH
Estrogen-Induced Neuroprotective Mitochondrial Mechanism$268,125
R01 · FY2004 · MH
Estrogen-Induced Neuroprotective Mitochondrial Mechanism$268,125
R01 · FY2003 · MH
ESTROGENIC STEROIDS--NEUROTROPHIC ACTION AND MECHANISM$137,803
P01 · FY2001 · AG
ESTROGENIC STEROIDS--NEUROTROPHIC ACTION AND MECHANISM$0
P01 · FY2001 · AG
ESTROGENIC STEROIDS--NEUROTROPHIC ACTION AND MECHANISM$157,152
P01 · FY2000 · AG